

G α i2-mediated signaling events in the endothelium are involved in controlling leukocyte extravasation

Ralph S. Pero, Michael T. Borchers, Karsten Spicher, Sergei I. Ochkur, Lyudmila Sikora, Savita P. Rao, Hiam Abdala-Valencia, Katie R. O'Neill, Huahao Shen, Michael P. McGarry, Nancy A. Lee, Joan M. Cook-Mills, P. Sriramaraio, Melvin I. Simon, Lutz Birnbaumer, and James J. Lee

PNAS published online Mar 7, 2007;
doi:10.1073/pnas.0700185104

This information is current as of March 2007.

Supplementary Material

Supplementary material can be found at:
www.pnas.org/cgi/content/full/0700185104/DC1

This article has been cited by other articles:
www.pnas.org/otherarticles

E-mail Alerts

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Rights & Permissions

To reproduce this article in part (figures, tables) or in entirety, see:
www.pnas.org/misc/rightperm.shtml

Reprints

To order reprints, see:
www.pnas.org/misc/reprints.shtml

Notes:

G α_{i2} -mediated signaling events in the endothelium are involved in controlling leukocyte extravasation

Ralph S. Pero^a, Michael T. Borchers^{b,c}, Karsten Spicher^d, Sergei I. Ochkur^b, Lyudmila Sikora^e, Savita P. Rao^e, Hiam Abdala-Valencia^f, Katie R. O'Neill^b, Huahao Shen^{a,g}, Michael P. McGarry^{b,h}, Nancy A. Lee^a, Joan M. Cook-Mills^f, P. Sriramara^g, Melvin I. Simon^{i,j}, Lutz Birnbaumer^k, and James J. Lee^{b,l}

Divisions of ^aHematology/Oncology and ^bPulmonary Medicine, Department of Biochemistry and Molecular Biology, Mayo Clinic Arizona, Scottsdale, AZ 85259; ^cDivision of Environmental Genetics and Molecular Toxicology, Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH 45267; ^dInstitute of Biochemistry and Molecular Biology, Heinrich Heine University, 40225 Düsseldorf, Germany; ^eDivision of Vascular Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121; ^fAllergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611; ^gDepartment of Respiratory Medicine, Second Hospital, Zhejiang University College of Medicine, Hangzhou 310009, China; ^hAnimal Care and Technologies, Arizona State University, Tempe, AZ 85287; ⁱDivision of Biology, California Institute of Technology, Pasadena, CA 91125; and ^kLaboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709

Contributed by Melvin I. Simon, January 9, 2007 (sent for review November 14, 2006)

The trafficking of leukocytes from the blood to sites of inflammation is the cumulative result of receptor-ligand-mediated signaling events associated with the leukocytes themselves as well as with the underlying vascular endothelium. Our data show that G α_i signaling pathways in the vascular endothelium regulate a critical step required for leukocyte diapedesis. *In vivo* studies using knockout mice demonstrated that a signaling event in a non-lymphohematopoietic compartment of the lung prevented the recruitment of proinflammatory leukocytes. Intravital microscopy showed that blockade was at the capillary endothelial surface and *ex vivo* studies of leukocyte trafficking demonstrated that a G α_i -signaling event in endothelial cells was required for transmigration. Collectively, these data suggest that specific G α_{i2} -mediated signaling between endothelial cells and leukocytes is required for the extravasation of leukocytes and for tissue-specific accumulation.

G proteins | inflammation | knockout mice | leukocyte trafficking | pulmonary models

The tissue-specific recruitment of polymorphonucleated granulocytes (i.e., neutrophils, basophils, and eosinophils) and lymphocytes has been particularly well studied, including the mechanisms mediating leukocyte tethering, rolling, adhesion, and eventual transmigration from the circulation (1). These studies have suggested that receptor–ligand interactions coupled to G α_i -containing heterotrimeric G proteins in leukocytes are particularly important for the vectorial movement of leukocytes to tissues in response to chemokine gradients (2). Thus, these receptors represent potential drug targets for therapeutic approaches directed against inflammatory diseases (3).

The activation of G α_i -coupled receptors leads to the dissociation of the heterotrimeric G protein and intracellular signaling events mediated by the release of the G α_i subunit (G α_i) bound to GTP and the free G $\beta\gamma$ dimer (4). The G α_i family includes genes encoding the subunits G α_{i1} , G α_{i2} , G α_{i3} , G α_o , and G α_z (5). The activities of G α_i family members, with the exception of G α_z , are distinguishable from other G α subunits by their susceptibility to pertussis toxin (PTX). The G α_{i1} , G α_{i2} , and G α_{i3} subunits are expressed in many leukocytes and tissues involved in allergic inflammation such as granulocytes (6), lymphocytes (7), airway smooth muscle (8), airway epithelium (8), and endothelial cells (9). Leukocytes that express these G α_i family members appear to express all three G α_i subunits simultaneously. However, studies assessing expression and function have suggested that heterotrimeric complexes containing G α_{i2} and G α_{i3} are abundant in leukocytes (2). Moreover, the importance of G α_i -mediated signaling events in leukocyte recruitment/accumulation has been highlighted by using mouse models capitalizing on the inhibitory character of PTX (6). However, the specific mechanisms and, more importantly, the relevant cell types

involved in facilitating leukocyte accumulation remain largely unknown.

Results and Discussion

G α_{i2} -Signaling Pathways in a Resident Cell of the Lung Are Required for the Accumulation of Eosinophils After Allergen Provocation. The recruitment and accumulation of eosinophils in the airway lumen and lung tissue after allergen provocation is a defining feature found in both asthma patients (10) and animal models of allergic respiratory inflammation (11). G α_i -coupled CCR3 receptor–ligand interactions promoting chemotaxis are primarily responsible for the allergen-induced accumulation of pulmonary eosinophils (12). G α_{i2} and G α_{i3} transcripts dominate the mRNAs encoding the PTX-sensitive G α_i subunits of mouse peripheral blood eosinophils (supporting information (SI) Fig. 5). We therefore examined mice deficient in either G α_{i2} or G α_{i3} for airway eosinophilia during asthma induced by sensitization and aerosol challenge with ovalbumin (OVA). The accumulation of eosinophils in the airway lumen of G $\alpha_{i2}^{-/-}$ mice was significantly reduced relative to wild-type animals (Fig. 1A), but induced eosinophilia in G $\alpha_{i3}^{-/-}$ was unaffected (Fig. 1B). A similar reduction in eosinophil accumulation was seen in the peribronchial areas of the lungs from G $\alpha_{i2}^{-/-}$ mice but not G $\alpha_{i3}^{-/-}$ mice relative to wild-type animals (SI Figs. 6 and 7). These data indicate that G α_{i2} -dependent signaling pathways are required for eosinophil entry into tissues from the circulation.

In vitro chemotaxis assays demonstrated that the loss of G α_{i2} signaling in eosinophils did not prevent G α_i -coupled receptor-mediated chemotaxis (e.g., CCR3-mediated responses to eotaxin-1/-2; ref. 12); instead, the loss of G α_{i2} may have even enhanced the ability of the granulocytes to respond to chemoattractant (Fig. 1C). Furthermore, these studies showed that the eotaxin-CCR3-mediated chemotactic response of G α_{i2} -deficient eosinophils was abolished by PTX (Fig. 1D), demonstrating that the signal transduction pathways mediating chemotaxis used the

Author contributions: R.S.P., M.T.B., S.I.O., N.A.L., M.I.S., L.B., and J.J.L. designed research; R.S.P., M.T.B., S.I.O., L.S., S.P.R., H.A.-V., K.R.O., H.S., and M.P.M. performed research; K.S., L.S., S.P.R., H.A.-V., J.M.C.-M., P.S., M.I.S., and L.B. contributed new reagents/analytic tools; R.S.P., M.T.B., S.I.O., H.S., M.P.M., N.A.L., J.M.C.-M., P.S., M.I.S., and J.J.L. analyzed data; and R.S.P., M.T.B., J.M.C.-M., P.S., M.I.S., and J.J.L. wrote the paper.

The authors declare no conflict of interest.

Abbreviations: PTX, pertussis toxin; OVA, ovalbumin; VCAM, vascular cell adhesion molecule; BAL, bronchoalveolar lavage; PBS, phosphate-buffered saline.

To whom correspondence may be addressed. E-mail: simonm@caltech.edu.

To whom correspondence may be addressed at: Mayo Clinic Arizona, SCIMRB RESEARCH, 13400 East Shea Boulevard, Scottsdale, AZ 85259. E-mail: jlee@mayo.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0700185104/DC1.

© 2007 by The National Academy of Sciences of the USA




Fig. 3. The loss of $G\alpha_{i2}$ signaling in knockout mice leads to nonspecific increases in all circulating white blood cell types and severely limits LPS-induced airway neutrophil accumulation. (A) Increase in all white blood cell types is observed in both allergen-naïve and OVA-treated $G\alpha_{i2}^{-/-}$ mice. The data presented represent means \pm SEM ($n = 5$ mice per group). *, significantly different ($P < 0.05$) from wild-type saline control mice. †, significantly different ($P < 0.05$) from OVA-treated wild-type mice. (B) LPS administered to $G\alpha_{i2}^{-/-}$ or $G\alpha_{i3}^{-/-}$ mice ($n = 7$ – 10 mice per group; wild-type animals served as negative controls) showed that the induced BAL neutrophil levels 16 h after administration were significantly decreased in $G\alpha_{i2}^{-/-}$ mice but unaffected in $G\alpha_{i3}^{-/-}$ animals. *, $P < 0.05$. (C) Transwell chemotaxis assays demonstrated that in the absence of $G\alpha_{i2}$ signaling events, *in vitro* neutrophil migration to MIP-2 was not lower but instead nominally higher relative to wild type.

cell exodus from the circulation. Once out of the vasculature, the leukocytes appear to have the ability to traffic along chemoattractant gradients and accumulate within specific tissue compartments.

Leukocyte Diapedesis and, in Turn, Tissue Accumulation Occurs as a Function of a $G\alpha_{i2}$ -Signaling Event(s) in Endothelial Cells. Because our results suggested a leukocyte-independent impairment early in leukocyte trafficking from the blood, we next used intravital microscopy to examine endothelial cell–leukocyte interactions to determine whether a $G\alpha_{i2}$ deficiency in endothelial cells alters interactions with leukocytes in such a way as to limit extravasa-

tion. Visualization of abdominal mesenteric postcapillary venules from wild-type and $G\alpha_{i2}^{-/-}$ mice (Fig. 4A and SI Movie 1) after systemic i.p. administration of LPS [$10 \mu\text{g}$ in $100 \mu\text{l}$ of phosphate-buffered saline (PBS)] demonstrated enhanced accumulation of stationary leukocytes on the endothelial surfaces in $G\alpha_{i2}^{-/-}$ animals relative to wild-type mice. Specifically, quantitative assessments of the leukocytes adhering to the venules demonstrated that whereas LPS exposure of wild-type mesentery induced only a nominal increase in static adherence to the underlying endothelium, the loss of $G\alpha_{i2}$ led to a >7 -fold increase in the number of immobilized leukocytes (Fig. 4A and SI Fig. 10). This greater number of stationary leukocytes in knockout mice could be a consequence of enhanced cell adhesion mediated by the absence of a $G\alpha_{i2}$ -signaling event(s) in the endothelium. Alternatively, the loss of $G\alpha_{i2}$ in the endothelium of knockout mice may slow down or block diapedesis, increasing the steady-state number of static endothelial-bound leukocytes which “back-up” on the endothelial surface. Our observation that all leukocyte subtypes accumulate in the blood of $G\alpha_{i2}^{-/-}$ mice, together with data demonstrating that different leukocyte subtypes use diverse repertoires of receptor–ligand interactions to mediate adhesion, suggest that a $G\alpha_{i2}$ -dependent effect on cell adhesion is unlikely. This conclusion was confirmed by using *ex vivo* laminar flow assays to assess lymphocyte adherence and migration through an endothelial cell monolayer (Fig. 4B and C). In these studies, $G\alpha_i$ -signaling events were abolished in the endothelial cell monolayer by pretreatment with PTX. This pretreatment of the endothelial cells had no effect on cytotoxicity/viability or surface expression levels of the vascular cell adhesion molecule 1 (VCAM-1) (SI Figs. 11 and 12, respectively). The laminar flow study showed that α_4 -integrin/VCAM-1-dependent firm adhesion of lymphocytes was unaffected in the absence of endothelial cell $G\alpha_i$ signaling (Fig. 4B), suggesting that effects on adhesion mediated by endothelial $G\alpha_{i2}$ signaling were not responsible for the blockade of leukocyte recruitment in knockout mice. However, the subsequent migration of firmly adherent lymphocytes through the endothelial cell monolayer (i.e., transmigration) in the laminar flow assay showed that this process was significantly inhibited after PTX treatment (i.e., a $G\alpha_i$ -dependent event) of the monolayer (Fig. 4C). This result suggests that a signaling event(s) in the venule endothelium of $G\alpha_{i2}^{-/-}$ mice specifically is required for efficient transmigration/diapedesis.

Activated leukocyte trafficking and, in particular, the specificity involved in the extravasation cascade, requires a complex exchange of signals (“handshakes”) between the mobile activated leukocytes and underlying vascular endothelial cells. The general responses of leukocytes and endothelial cells to chemokines have been studied (19) as has the role of adhesion molecules and their receptors in the trafficking response (20). The involvement of $G\alpha_i$ -coupled receptors in leukocyte activation, rolling, and subsequent arrest at the endothelial surface before diapedesis has been shown to involve a PTX-sensitive step at the level of the leukocyte (e.g., $G\alpha_i$ -coupled chemokine-mediated recruitment). However, our data also suggest that the complex interaction between endothelial cells and leukocytes responding to inflammatory signals includes a signal transduction event involving the $G\alpha_{i2}$ isoform in endothelial cells, which leads to the extravasation of circulating leukocytes. The activation of this pathway may occur in several different ways. For example, the interaction of endothelial cells with leukocytes activates a variety of ectoenzymes. Thus, transmigration may require a $G\alpha_{i2}$ -mediated response in the endothelial cells to signals or ligands generated by these ectoenzymes (reviewed in ref. 21). Alternatively, local changes in nitric oxide have been shown to modify the levels of RGS (Regulators of G protein Signaling) proteins that are required for regulating $G\alpha_{i2}$ -signaling events in endothelial cells (22). Moreover, “outside-in”

Isolation of Mouse Eosinophils, Isolation of Splenocytes, and *In Vitro* Assessment of Leukocyte Chemotaxis. For details, see *SI Materials and Methods*.

Eosinophil Adoptive Transfer and *Ex Vivo* Labeling of Eosinophils and Monitoring the Recruitment/Accumulation of Labeled Eosinophils Following Adoptive Transfer to the Peritoneal Cavity. For details, see *SI Materials and Methods*.

Hematopoietic Engraftment by Bone Marrow Transfer. Exposing female wild-type mice to 1,100-cGy whole body lethal irradiation generated complete bone marrow chimeras. Within 3 h of irradiation, 1×10^7 bone marrow cells from wild-type or $G\alpha_{i2}^{-/-}$ male donors were transferred by tail vein injection. Engrafted mice were used in experiments after a >45-day recovery period. Recovered mice were sensitized and aerosol challenged with OVA (saline for controls) by using the protocol noted above, and BAL eosinophils were enumerated 24 h after the last challenge. Eosinophils comprise <1% of leukocytes in the airways of saline-challenged mice of any group. Donor cell engraftment of >90% was achieved in all recipients as determined by a PCR assay designed to quantify X vs. Y chromosome-specific sequences (29).

Cytokine Assays. Cytokine levels in BAL fluid were determined by ELISA. Mouse IL-4, IL-5, IFN- γ , and IL-12 ELISA kits (R&D Systems, Minneapolis, MN) were used according to the manufacturer's protocol. The limits of detection for each assay were as follows: IFN- $\gamma \approx 30$ pg/ml, IL-4 ≈ 10 pg/ml, IL-5 ≈ 10 pg/ml, and IL-12 ≈ 10 pg/ml.

In Vivo* Assessment of Leukocyte Intracapillary Rolling and/or Adhesion in Postcapillary Venules by Intravital Microscopy and *Ex Vivo

Assessments of Lymphocyte Adhesion and Migration. For details, see *SI Materials and Methods*.

Determination of VCAM-1 Endothelial Cell Expression Using Flow Cytometry. mHEV α endothelial cell monolayers (before or after exposure to PTX) were disassociated into single-cell suspensions by using 0.3% EDTA, and the recovered cells were washed in RPMI-1640 containing 20% FCS. Cells were stained in PBS/0.5% BSA/0.15% NaN $_3$ with rat anti-mouse VCAM-1 antibody (normal rat IgG was used as a negative control for primary antibody staining) and visualized with biotin-conjugated goat anti-rat antibodies and streptavidin-phycoerythrin. Analysis was performed on a FACScan flow cytometer (BD Biosciences, Palo Alto, CA) with CellQuest Pro software (BD Biosciences).

Statistical Analysis. All data presented are the means \pm standard errors (SEM). Statistical analysis was performed on parametric data by using *t* tests with differences between means considered significant when $P < 0.05$.

We thank numerous individuals, including Dana Colbert, Tracy L. Ansay, Edith M. Hines, Travis Biechele, and Alfred D. Doyle. We also thank the Mayo Clinic Arizona Core facilities (Histology, Lisa Barbarisi; Immunology, Tammy Brehm-Gibson; Mouse Special Animal Services, Suresh Savarirayan; Medical Graphic Arts, Marv Ruona; Video Production and Services, Randall J. Raish; Research Library Services, Joseph Esposito). In addition, we thank our administrative staff, Linda Mardel and Margaret (Peg) McGarry. This work was supported in part by the Mayo Foundation and grants from the National Institutes of Health to J.J.L. (HL065228 and K26-RR019709), N.A.L. (HL058723), J.M.C.-M. (HL68171), P.S. (AI35796 and HL079304), M.I.S. (GM34236), and L.B. (DK-19318).

- Worthylake RA, Burridge K (2001) *Curr Opin Cell Biol* 13:569–577.
- Jiang M, Spicher K, Boulay G, Martin-Requero A, Dye CA, Rudolph U, Birnbaumer L (2002) *Methods Enzymol* 344:277–298.
- Wise A, Gearing K, Rees S (2002) *Drug Discov Today* 7:235–246.
- Wettchuck N, Offermanns S (2005) *Physiol Rev* 85:1159–1204.
- Wilkie TM, Gilbert DJ, Olsen AS, Chen, X-N, Amatruda TT, Korenberg JR, Trask BJ, de Jong P, Reed RR, Simon MI, et al. (1992) *Nat Genet* 1:85–91.
- Goldman DW, Chang FH, Gifford LA, Goetzl EJ, Bourne HR (1985) *J Exp Med* 162:145–156.
- Rudolph U, Spicher K, Birnbaumer L (1996) *Proc Natl Acad Sci USA* 93:3209–3214.
- Emala CW, Yang J, Hirshman CA, Levine MA (1994) *Life Sci* 55:593–602.
- Fabian G, Szabo CA, Bozo B, Greenwood J, Adamson P, Deli MA, Joo F, Krizbai IA, Szucs M (1998) *Neurochem Int* 33:179–185.
- Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Francois-Bernard M (1990) *N Engl J Med* 323:1033–1039.
- Kips JC, Anderson GP, Fredberg JJ, Herz U, Inman MD, Jordana M, Kemeny DM, Lotvall J, Pauwels RA, Plopper CG, et al. (2003) *Eur Respir J* 22:374–382.
- Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME (2005) *J Immunol* 175:5341–5350.
- Lee NA, McGarry MP, Larson KA, Horton MA, Kristensen AB, Lee JJ (1997) *J Immunol* 158:1332–1344.
- Han SB, Moratz C, Huang NN, Kelsall B, Cho H, Shi CS, Schwartz O, Kehl JH (2005) *Immunity* 22:343–354.
- Finsnes F, Skjongsberg OH, Lyberg T, Christensen G (2000) *Eur Respir J* 15:743–750.
- Keil ML, Solomon NL, Lodhi JJ, Stone KC, Jesaitis AJ, Chang PS, Linderman JJ, Omann GM (2003) *Biochem Biophys Res Commun* 301:862–872.
- Ley K (2004) *Am J Physiol Lung Cell Mol Physiol* 286:L463–L464.
- Jiang H, Kuang Y, Wu Y, Xie W, Simon MI, Wu D (1997) *Proc Natl Acad Sci USA* 94:7971–7975.
- Moser B, Wolf M, Walz A, Loetscher P (2004) *Trends Immunol* 25:75–84.
- Springer TA (1994) *Cell* 76:301–314.
- Salmi M, Jalkanen S (2005) *Nat Rev Immunol* 5:760–771.
- Hu RG, Sheng J, Qi X, Xu Z, Takahashi TT, Varshavsky A (2005) *Nature* 437:981–986.
- Barreiro O, Yanez-Mo M, Sala-Valdes M, Gutierrez-Lopez MD, Ovalle S, Higginbottom A, Monk PN, Cabanas C, Sanchez-Madrid F (2005) *Blood* 105:2852–2861.
- van Buul JD, Anthony EC, Fernandez-Borja M, Burridge K, Hordijk PL (2005) *J Biol Chem* 280:21129–21136.
- Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L (1995) *Nat Genet* 10:143–150.
- Borchers MT, Crosby JR, Farmer SC, Sypek J, Ansay TL, Lee NA, Lee JJ (2001) *Am J Physiol* 280:L813–L821.
- Lundy SK, Berlin AA, Lukacs NW (2003) *Am J Pathol* 163:1961–1968.
- Denzler KL, Farmer SC, Crosby JR, Borchers MT, Cieslewicz G, Larson KA, Cormier-Regard S, Lee NA, Lee JJ (2000) *J Immunol* 165:5509–5517.
- Novak EK, Reddington M, Zhen L, Stenberg PE, Jackson CW, McGarry MP, Swank RT (1995) *Blood* 85:1781–1789.